The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19

被引:21
|
作者
Yang, Rongrong [1 ]
Xiong, Yong [1 ]
Ke, Hengning [1 ]
Chen, Tielong [1 ]
Gao, Shicheng [1 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Donghu Rd 169, Wuhan 430071, Peoples R China
关键词
COVID-19; cytokine storm; methylprednisolone; prognosis; SARS-CoV-2; ACUTE RESPIRATORY SYNDROME; CLINICAL CHARACTERISTICS; CORTICOSTEROID TREATMENT; INFLUENZA; PNEUMONIA; MORTALITY; HYDROCORTISONE;
D O I
10.1111/eci.13412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background COVID-19 is a public health emergency that is spreading worldwide and seriously affecting the global economy. Data on the effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 remain limited. Methods In this retrospective study, epidemiological, clinical, laboratory, treatment and outcomes data of hospitalized patients with severe COVID-19 in Zhongnan Hospital of Wuhan University from January 1 to 7 March 2020, were collected. Binary logistic regression model was used to analyse risk factors for disease progression from severe COVID-19 illness to critical illness. The effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 disease were evaluated. Results The results of the multivariate analysis from 175 patients with severe COVID-19 indicate that the use of methylprednisolone was a protective factor against disease progression from severe to critical illness(P < .001; OR: 0.054 95% CI: 0.017-0.173). Among patients with severe COVID-19 aged < 65 years, both the proportion of patients who progressed to critical illness (42.2% vs 90.0%,P = .000) and the mortality(6.7% vs 30.0%,P = .002) were lower for patients in methylprednisolone group, compared with those in the non-methylprednisolone group, whereas no statistical differences between the methylprednisolone group and the non-methylprednisolone group were found among patients with COVID-19 older than 65 years. Moreover, both the levels of CD4(+)T lymphocyte counts (646 vs 463/mu L,P = .007) and IL-6 (241.9 vs 82.8 pg/mL,P = .025) were higher among patients with severe COVID-19 aged < 65 years, compared with those patients >= 65 years old. Conclusion Data from the limited sample showed that the early use of low or medium doses of methylprednisolone has a positive effect for patients with severe COVID-19 younger than 65 years old, and excessive immune response and cytokine storm may be some of the reasons for the effectiveness.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19
    Falcone, Marco
    Suardi, Lorenzo Roberto
    Tiseo, Giusy
    Barbieri, Chiara
    Giusti, Lisa
    Galfo, Valentina
    Forniti, Arianna
    Caroselli, Claudio
    Della Sala, Leonardo
    Tempini, Sara
    Okoye, Chukwuma
    Monzani, Fabio
    Menichetti, Francesco
    CLINICAL THERAPEUTICS, 2022, 44 (03) : 364 - 373
  • [32] The AIFELL Score as a Predictor of Coronavirus Disease 2019 (COVID-19) Severity and Progression in Hospitalized Patients
    Levenfus, Ian
    Ullmann, Enrico
    Petrowski, Katja
    Rose, Jutta
    Huber, Lars C.
    Stuessi-Helbling, Melina
    Schuurmans, Mace M.
    DIAGNOSTICS, 2022, 12 (03)
  • [33] Temporal patterns of cytokine and injury biomarkers in hospitalized COVID-19 patients treated with methylprednisolone
    Mwangi, Victor Irungu
    Netto, Rebeca Linhares Abreu
    de Morais, Carlos Eduardo Padron
    Silva, Arineia Soares
    Silva, Bernardo Maia
    Lima, Amanda Barros
    Neves, Juliana Costa Ferreira
    Borba, Mayla Gabriela Silva
    Val, Fernando Fonseca de Almeida e
    de Almeida, Anne Cristine Gomes
    Costa, Allyson Guimaraes
    Sampaio, Vanderson de Souza
    Gardinassi, Luiz Gustavo
    de Lacerda, Marcus Vinicius Guimaraes
    Monteiro, Wuelton Marcelo
    de Melo, Gisely Cardoso
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [34] Successful use of methylprednisolone for treating severe COVID-19
    Liu, Jing
    Zheng, Xiaobin
    Huang, Yiying
    Shan, Hong
    Huang, Jin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (02) : 325 - +
  • [35] Intravenous pulse methylprednisolone for the treatment of severe COVID-19
    Patoulias, Dimitrios
    Dimosiari, Athina
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 110 : 107 - 109
  • [36] Effect of mRNA Vaccines in Preventing COVID-19 Severe Pneumonia Among COVID-19 Patients in Japan
    Matsuo, Rumi
    Matsumoto, Naomi
    Kadowaki, Tomoka
    Mitsuhashi, Toshiharu
    Takao, Soshi
    Yorifuji, Takashi
    JOURNAL OF EPIDEMIOLOGY, 2022, 32 (03) : 151 - 152
  • [37] Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19
    Liu, Ze-Ming
    Li, Jin-Peng
    Wang, Shi-Pei
    Chen, Dan-Yang
    Zeng, Wen
    Chen, Si-Chao
    Huang, Yi-Hui
    Huang, Jiang-Long
    Long, Wei
    Li, Man
    Gao, Rong-Fen
    Guo, Liang
    Wu, Xiao-Hui
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (16): : 2468 - 2476
  • [38] Pulmonary embolism in non-hospitalized COVID-19 infected patients without severe disease
    Evbuomwan, O.
    Engelbrecht, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S405 - S406
  • [39] HIGH LEVELS OF TRANSAMINASES AT ADMISSION PREDICT A SEVERE DISEASE COURSE IN COVID-19 HOSPITALIZED PATIENTS
    Pelizzaro, F.
    Kitenge, M. P.
    Maran, F.
    Cocconcelli, E.
    Balestro, E.
    Spagnolo, P.
    Cattelan, A.
    Farinati, F.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S106 - S106
  • [40] Severe COVID-19 Progression in a Welder
    Knoop, H.
    Knoop, U.
    PNEUMOLOGIE, 2021, 75 : S15 - S15